Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ITP according to American Society of Hematology (ASH) guidelines at least 3 months before enrollment~* Have completed at least 1 prior treatment for ITP~* Two (including day -2) of the 3 platelet counts taken during the screening and pre-treatment periods must have fulfilled the following:~  * less than 30 x 10\^9/L for those subjects not receiving any ITP therapy,~ * less than 50 x 10\^9/L for those subjects receiving any ITP therapy~* Eastern Cooperative Oncology Group performance status of 0 to 2~* Serum creatinine concentration ≤ 2 mg/dL (≤ 176.8 µmol/L)~* Adequate liver function, as evidenced by a serum bilirubin ≤ 1.5 times the laboratory normal range~* Hemoglobin greater than 10.0 g/dL~* Written informed consent~Exclusion Criteria:~* Considered a substantial risk for adverse outcomes because of a clinically important trend (as determined by the investigator) detected in the platelet counts during the screening period~* Any known history of bone marrow stem cell disorder~* Any active malignancy. If prior history of cancer other than basal cell carcinoma or cervical carcinoma in situ, no treatment or active disease within 5 years before randomization~* Documented diagnosis of arterial thrombosis (ie, stroke, transient ischemic attack, or myocardial infarction) in the previous year; history of venous thrombosis (ie, deep vein thrombosis, pulmonary embolism) and receiving anticoagulation therapy~* Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure \[New York Heart Association (NYHA) greater than class II\], uncontrolled hypertension \[diastolic greater than 100 mmHg\] or cardiac arrhythmia)~* Have 3 or more of the following predisposing factors for thromboembolic events: diabetes; smoker using oral contraceptives; hypercholesteremia (\> 240 mg/dL); treatment for hypertension~* Known positive test for human immunodeficiency virus (HIV) infection or hepatitis C virus~* Received any treatment for ITP (except for a constant dose schedule of corticosteroids) within 4 weeks before the screening visit~* Received intravenous (IV) immunoglobulin (Ig) or WinRho within 2 weeks before the screening visit~* Received hematopoietic growth factors, including interleukin (IL)-11 (Neumega®) within 4 weeks before the screening visit~* Past or present participation in any study evaluating polyethylene glycol recombinant human magakaryopoiesis differentiating factor (PEG-rHuMGDF), recombinant human thrombopoietin (rHuTPO), or related platelet product~* Received any alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study~* Received any monoclonal antibody (eg, rituximab) within 16 weeks before the screening visit or anticipated use during the time of the proposed study~* Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication before the screening period~* Less than 2 months since major surgery (including laparoscopic splenectomy)~* Pregnant or breast feeding~* Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Romiplostim 0.2 µg/kg (Type: EXPERIMENTAL): Participants received 0.2 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
- Part A: Romiplostim 0.5 µg/kg (Type: EXPERIMENTAL): Participants received 0.5 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
- Part A: Romiplostim 1.0 µg/kg (Type: EXPERIMENTAL): Participants received 1.0 µg/kg romiplostim subcutaneously on day 1 and on day 15 or 22 depending on platelet counts.
- Part A: Romiplostim 3 µg/kg (Type: EXPERIMENTAL): Participants received 3.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
- Part A: Romiplostim 6 µg/kg (Type: EXPERIMENTAL): Participants received 6.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
- Part A: Romiplostim 10 µg/kg (Type: EXPERIMENTAL): Participants received 10.0 µg/kg romiplostim subcutaneously on day 1 and day 15 or 22, depending on platelet counts.
- Part B: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneously once a week for 6 weeks.
- Part B: Romiplostim 1.0 µg/kg (Type: EXPERIMENTAL): Participants received 1.0 µg/kg subcutaneously once a week for 6 weeks.
- Part B: Romiplostim 3.0 µg/kg (Type: EXPERIMENTAL): Participants received 3.0 µg/kg subcutaneously once a week for 6 weeks.
- Part B: Romiplostim 6.0 µg/kg (Type: EXPERIMENTAL): Participants received 6.0 µg/kg subcutaneously once a week for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete